Conference Reports for NATAP

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention July 19th-22nd 2009 Capetown, South Africa Back

The MERIT Study of Maraviroc in Antiretroviral-Naive Patients With R5 HIV-1: 96-Week Results       Reported by Jules Lein 5th IAS Capetown July 19-22 2009   Heera J, Ive P, Botes M, DeJesus E, Mayer H, Goodrich J, Clumeck N, Cooper D, Walmsley S, Craig C, Reeves J, van der Ryst E and Saag M MERIT ES MERIT ES * Adjusted for randomization strata Includes all patients with R5 virus at screening by enhanced Trofile assay who received at least one dose of study medication; missing values classified as failures/non-responders; MERIT-ES per-protocol analysis (MVC+CBV N=285; EFV+CBV N=268): < 50 copies/mL difference = -0.029 (-10.7)   MERIT ES MERIT ES * Week 48 or 96 mean value adjusted for randomization strata Last observation carried forward; blinded therapy values only. Includes all patients with R5 virus at screening by enhanced Trofile assay who received at least one dose of study medication   MERIT ES Only patients with an R5 screening result by enhanced Trofile assay are included * 12% of patients on MVC and 9% on EFV switched to other NRTI backbones over 96 weeks Includes one death in the MVC arm at week 48 and two deaths each in the MVC and EFV arms at week 96   At week 96, 45 patients in each treatment group (15% and 14% in the EFV and MVC groups, respectively) had experienced a serious adverse event (compared to 34 [11%] and 32 [10%] patients at week 48)   MERIT MERIT MERIT * At one or more on-study assessments (fasting lipoprotein profiles were obtained for each patient at week 24 and week 48, or at early termination) As defined by NCEP guidelines P-values are for comparisons of proportions (Pearson's chi-square test)